Send to

Choose Destination
Lung India. 2019 Nov-Dec;36(6):525-533. doi: 10.4103/lungindia.lungindia_38_19.

Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies.

Author information

Department of Respiratory Medicine, Centre for Chest and Respiratory Disease, BLK Super Speciality Hospital, New Delhi, India.
Department of Respiratory Medicine, Deccan College of Medical Sciences, Hyderabad, Telangana, India.
Department of Respiratory Medicine, Kunal Institute of Pulmonology, Hyderabad, Telangana, India.
Department of Critical Care Medicine, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India.
Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra, India.


Community-acquired bacterial pneumonia (CABP) is one of the leading causes of morbidity and mortality in India and worldwide. Evidence indicates that Gram-positive, Gram-negative, and atypical bacteria are encountered with near-equal frequency. Despite guideline recommendations and antibiotic options for the management of CABP, burden of morbidity and mortality is high, which is attributable to a variety of factors. Failure of empirical therapy, probably because of insufficient microbial coverage, increasing bacterial resistance, and adverse effects of existing treatments, underlies the unsuccessful treatment of CABP, especially in India. Multiple novel therapies that have entered clinical development phases have potential to address some of these issues. This article discusses the current treatment guidelines in CABP, management limitations, and emerging potential treatment options in the management of CABP.


Adult; antibiotic; bacteria; community acquired bacterial pneumonia; resistance

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center